Accueil > Actualité
Actualite financiere : Actualite bourse

Eli Lilly: lung cancer drug shows positive response rate

( - An experimental oral drug developed by Eli Lilly has showed "positive results" in patients with non-small cell lung cancer, the US company said on Monday.

In the first 105 enrolled RET-altered cancer patients with prior chemotherapy, selpercatinib treatment resulted in a 68% objective response rate, the drugmaker said.

In treatment-naïve RET fusion-positive non-small cell lung cancer patients, selpercatinib resulted in an 85% response rate in the analysis of 34 patients, it added.

Following these results, Lilly said that it is looking forward to submitting a new drug application by the end of the year.

Copyright (c) 2019 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.